Celcuity's Q3 2025 results reflected higher operating expenses, particularly in research and development and administrative functions, contributing to a larger net loss. Despite no revenue, the company made key progress in its clinical trials and regulatory pipeline.

Celcuity significantly increased R&D investments in Q2 2025 to advance gedatolisib clinical programs. The net loss widened, but the company’s strengthened balance sheet is expected to fund operations through 2027.

Celcuity posted a net loss of $37.0 million for Q1 2025, primarily driven by a significant increase in research and development expenses related to its Phase 3 trials. Despite no reported revenue, the company maintained a strong cash position of over $205 million, sufficient to fund clinical programs through 2026. The company expects multiple data readouts from its ongoing studies later this year.

Celcuity's fourth quarter results reflected a significant rise in R&D and administrative expenses, contributing to a wider net loss. However, the company ended the quarter with a strong cash position to support ongoing clinical development programs.

Celcuity reported a net loss of $29.8 million, or $0.70 loss per share, for the third quarter of 2024, compared to a net loss of $18.4 million, or $0.83 loss per share, for the third quarter of 2023. Total operating expenses were $30.1 million, compared to $18.9 million for the third quarter of 2023.

Celcuity's operating expenses increased to $24.3 million, driven by higher R&D spending related to the VIKTORIA-1 and CELC-G-201 clinical trials. The net loss was $23.7 million, or $0.62 per share, compared to a net loss of $14.6 million, or $0.66 per share, for the second quarter of 2023. Cash, cash equivalents and short-term investments totaled $283.1 million at the end of the quarter.

Celcuity reported a net loss of $21.6 million, or $0.64 loss per share, for the first quarter of 2024. The company's operating expenses were $22.5 million, with R&D expenses at $20.7 million and G&A expenses at $1.8 million. As of March 31, 2024, Celcuity reported cash, cash equivalents and short-term investments of $177.7 million.

Celcuity reported a net loss of $18.8 million for the fourth quarter of 2023, compared to a net loss of $11.6 million for the fourth quarter of 2022. The company's operating expenses were $19.7 million for the fourth quarter of 2023, compared to $11.6 million for the fourth quarter of 2022. At December 31, 2023, Celcuity reported cash, cash equivalents and short-term investments of $180.6 million.

Celcuity reported a net loss of $18.4 million, or $0.83 loss per share, for the third quarter of 2023, compared to a net loss of $10.9 million, or $0.75 loss per share, for the third quarter of 2022. Total operating expenses were $18.9 million for the third quarter of 2023, compared to $10.6 million for the third quarter of 2022. At September 30, 2023, Celcuity reported cash, cash equivalents and short-term investments of $133.9 million.

Celcuity reported a net loss of $14.6 million, or $0.66 loss per share, for the second quarter of 2023, compared to a net loss of $10.0 million, or $0.67 loss per share, for the second quarter of 2022. Total operating expenses were $15.1 million, and research and development expenses were $13.7 million. Cash, cash equivalents and short-term investments totaled $146.2 million at the end of the quarter.

Celcuity's total operating expenses were $12.5 million, with R&D expenses at $11.3 million and G&A expenses at $1.3 million. The net loss was $11.9 million, or $0.55 loss per share. Non-GAAP adjusted net loss was $10.2 million, or $0.47 loss per share. The company had cash, cash equivalents, and short-term investments of $157.5 million at the end of the quarter.

Celcuity Inc. reported a net loss of $11.6 million, or $0.69 loss per share, for the fourth quarter of 2022, compared to a net loss of $6.8 million, or $0.45 loss per share, for the fourth quarter of 2021. The company's operating expenses were $11.6 million for the fourth quarter of 2022, compared to $6.3 million for the fourth quarter of 2021. At December 31, 2022, Celcuity had cash, cash equivalents and short-term investments of $168.6 million.

Celcuity reported a net loss of $10.9 million, or $0.75 loss per share, for the third quarter of 2022. Total operating expenses were $10.6 million, with R&D expenses at $9.6 million and G&A expenses at $1.0 million. The company's cash and cash equivalents stood at $57.5 million as of September 30, 2022.

Celcuity reported a net loss of $10.0 million for the second quarter of 2022, compared to a net loss of $14.0 million for the second quarter of 2021. The company's operating expenses were $9.6 million, and R&D expenses were $8.4 million. Celcuity had cash and cash equivalents of $66.9 million as of June 30, 2022.

Celcuity reported a net loss of $7.9 million, or $0.53 per share, for the first quarter of 2022. The company's cash and cash equivalents were $78.3 million as of March 31, 2022. They entered into a definitive securities purchase agreement expected to result in $100 million in gross proceeds.

Celcuity Inc. reported its Q4 and full year 2021 financial results, along with the design for its pivotal Phase 3 trial for gedatolisib and other business updates. The company's operating expenses and net loss increased compared to the same period in 2020, driven by increased R&D expenses related to the Pfizer license agreement and gedatolisib development.

Celcuity Inc. reported a net loss of $6.0 million for the third quarter of 2021, compared to a net loss of $2.5 million for the third quarter of 2020. The company's cash and cash equivalents were $90.4 million as of September 30, 2021.

Celcuity reported a net loss of $14.0 million for the second quarter of 2021, compared to a net loss of $2.2 million for the second quarter of 2020. The company's cash and cash equivalents were $41.6 million as of June 30, 2021, and after a follow-on equity offering in July, they had approximately $94.4 million of cash on hand.

Celcuity reported a net loss of $2.79 million for the first quarter of 2021, compared to a net loss of $2.25 million for the first quarter of 2020. The company's cash and cash equivalents were $34.9 million as of March 31, 2021, compared to $11.6 million at December 31, 2020. Celcuity entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib.

Celcuity Inc. reported a net loss of $2.55 million for the fourth quarter of 2020, compared to a net loss of $1.81 million for the fourth quarter of 2019. The company's operating expenses were $2.55 million, up from $1.90 million in the same quarter of the previous year. Celcuity had cash and cash equivalents of $11.6 million as of December 31, 2020.

Celcuity reported a net loss of $2.47 million, or $0.24 per share, for the third quarter of 2020. The company had cash and cash equivalents of $13.7 million as of September 30, 2020, which is expected to support operations through 2021.

Celcuity Inc. reported a net loss of $2.20 million, or $0.21 per share, for the second quarter of 2020. The company's cash and cash equivalents were $15.4 million as of June 30, 2020, which is expected to support operations through 2021.

Celcuity reported a net loss of $2.25 million, or $0.22 per share, for the first quarter of 2020, compared to a net loss of $1.85 million, or $0.18 per share, for the first quarter of 2019. Total operating expenses were $2.31 million for the first quarter of 2020, compared to $1.97 million for the first quarter of 2019.

Celcuity reported a net loss of $1.81 million, or $0.18 per share, for the fourth quarter of 2019. The company made significant progress advancing its CELsignia platform and expanded its Scientific Advisory Board.